Fabio Lopez

Director/Board Member at Sellas Life Sciences Group Ltd.

49 year

Health Technology

Profile

Fabio Lopez is currently a Director at Sellas Life Sciences Group Ltd.
He was previously a Director at SELLAS Life Sciences Group, Inc. from 2017 to 2018.

Fabio Lopez active positions

Companies	Position	Start
Sellas Life Sciences Group Ltd. Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland.	Director/Board Member	2017-12-28

All active positions of Fabio Lopez

Former positions of Fabio Lopez

Companies	Position	End
SELLAS LIFE SCIENCES GROUP, INC.	Director/Board Member	2018-07-26

See the detail of Fabio Lopez's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Fabio Lopez's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SELLAS LIFE SCIENCES GROUP, INC.	Health Technology

Private companies	1
Sellas Life Sciences Group Ltd. Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland.	Health Technology